Terran Bioscience Files New Patent, Adding to 4-OH-DiPT Drama

Terran Bioscience has filed a patent application for 4-OH-DiPT, adding another layer of patent intrigue around the lesser-known compound.

Salts and Solid Forms of 4-Hydroxy-N,N-Diisopropyltryptamine Hemi-Glutarate and Hemi-Succinate was filed by Terran Biosciences and has claims on a prodrug of 4-OH-DiPT, the same compound that both Mindset Pharma and Reuninon Neuroscience have patent claims on.

4-HO-DiPT is a psilocybin-like compound researched by the Shulgin’s and noted for its intense effects and shorter onset and trip time.

Reunion and Mindset have been competing over patent claims on this drug, with Reunion suing Mindset Pharma over its competing patent.

Now we have Terran Bioscience entering the 4-OH-DiPT race with its own patent application. Terran have been quite busy expnading their development portfolio and IP strategy. Microdose reached out to Terran for comment on the news:

“Companies like Reunion Neuroscience and Mindset Pharma have been publicly dueling over the IP around this compound, Terran has been working on making advances to the compound’s chemistry and innovating novel approaches that, to our knowledge, others have not pursued.

“While Terran is developing many compounds in-house, they have announced that they’ve made large data packages and IP portfolios available for licensing and partnerships to help advance the psychedelic industry as a whole, which would certainly be of interest to other companies looking to accelerate the development of their pipelines.”

For more on Terran, check out Terran Biosciences announces publication of four patent applications of novel empathogens and Terran Biosciences Announces Licensing Deal with Pierre Fabre for Idazoxan; Completes Development Milestones

The post Terran Bioscience Files New Patent, Adding to 4-OH-DiPT Drama appeared first on Microdose.

Read More